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Abstract 
The paper has measured the relationship between the in ellectual property rights and Foreign Direct 
Investment in the context of Indian biopharma Industry in order to know the impact of TRIPs agreement of 
WTO on the biopharmaceutical industry of developing countries. The central issue in this study is the 
extent to which patent reform (after the imposition of the TRIPs agreement in 1995) affects India’s ability 
to attract technology transfer for the biopharmaceuti al drugs innovation. For the same this study has done 
an analysis of FDI flow in biopharma industry in Pre TRIPs (before the imposition of product patent 
protection 1991-1999) and post TRIPs (after the product patent protection, 1999-2005) along with a 
comparative analysis of the relationship between the amount of foreign investment flown in different 
Indian states and the investment climate ranking of th se states which are the part of Indian biocluster.  
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Introduction 
Trade Related aspects of Intellectual Property Rights (TRIPs) agreement of the World 
Trade Organisation (WTO) is considered to be one of the milestones in the international 
harmonization of patent protection. As product patent protection has been imposed on all 
its member countries by its Article-27.1(1). Article-27.1 places a strict obligation on 
member to provide patents for all patentable pharmaceutical and biopharmaceutical 
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products. So, after the enforcement of the TRIPs agreement, there is a significant change 
in the patent regime in the developing countries mainly. Before TRIPs, a vast majority of 
developing countries such as Argentina, China, India, Korea and Mexico protected 
process but not product. After the enforcement of TRIPs agreement these countries will 
not be able to carry out reverse engineering(2).  In reverse engineering the new chemical 
entity or molecule is manufactured with new process, whose development cost is minimal 
and clinical testing are not required where as it takes several hundred million dollars to 
discover, develop and gain regulatory approval for a new medicine and without the 
capacity to spend for the innovation of new molecul(3). After the imposition of product 
patent protection, generic production of new biopharmaceutical drugs (i.e. those patented 
post 2005) are not allowed and the firms have to inn vate novel biopharma drugs. Indian 
biopharmaceutical industry is basically a biogeneric (4) industry. India is the supplier of 
cheap generic drugs to the world, main innovator prducts on which biogeneric drugs 
have been produced by the Indian biogeneric industry are Erythropoitin, G-CSF, 
recombinant Hepatitis B vaccine, Insulin, Interferon alfa, streptokinase etc.  On the one 
hand, there is heavy burden of diseases shares 18% of the worldwide mortality and 20% 
of the worldwide morbidity (5). On the other hand, there is limited resource to innovate 
novel drugs as India shares 2% of world GDP and invest just 1% on the healthcare of the 
world healthcare investment (6). So at the moment monetary resources to innovate novel 
drugs on its own strength for the generic biopharmaceutical industry of developing nation 
like India is not possible, therefore foreign direct investment (FDI) and foreign 
technology transfer is important to enter into the c ain of novel drug innovation. 
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This gives an important situation to study the impact of the TRIPs agreement on the 
biopharma drug innovation in India by foreign technology transfer. So, the study is 
concentrated on the Indian biopharmaceutical industry and attempts to analyse the effect 
of the product patent protection on the foreign technology transfer in biopharmaceutical 
(7) drugs innovation.  
It is also interesting to do such study as it has been argued by the developed countries that 
strengthening of patent protection will bring innovation through increased foreign direct 
investment and greater transference of technology in developing countries. At the same 
time, the objective of the TRIPs agreement which is stated in Article 7 also says; 
Protection and enforcement of Intellectual Property Rights should contribute to the 
promotion of 
- Technological innovation and transfer and disseminatio  of technology to the 
mutual advantage of producer and user of the technological knowledge. 
Thus, it can be interpreted that implementation of Art 27.1 will lead to greater foreign 
technology transfer in Pharma and biopharma sector. In Doha declaration too (Art 37)(5) 
it was agreed that the WTO would set up a working group to examine the relationship 
between trade and transfer of technology and to reprt findings to the fifth session of the 
Ministerial Conference (Art 38, 41)(6). 
In this way the relationship of two very Articles (Article 7 and 27) is interesting to 
analyse as the same will measure the relationship between the intellectual property rights 
and FDI in the context of Indian biopharma Industry in order to know the impact of 
TRIPs agreement on the biopharmaceutical industry of developing countries. 
 4
The central issue in this study is the extent to which patent reform (after the imposition of 
the TRIPs agreement in 1995) affects India’s ability to attract technology transfer for the 
biopharmaceutical drugs innovation. This is in order to see the impact of changed 
intellectual property protection on FDI and technology transfer.  
Further to investigate the actual role of IP in pulling FDI and technology transfer, this 
study has made a comparative analysis of the relationsh p between the amount of foreign 
investment and the investment climate ranking of the different states of India which are 
the part of Indian bioclusters. By investment climate we mean a menu of policy, 
regulatory and institutional factors that provide incentives sufficiently robust to induce 
private sector to invest in socially desirable projects (Weingast 1992)(8). According to 
Stern Investment climate is policy, institutional and behavioral environment both present 
and expected that influences the returns and risks a sociated with investment (Stern 2002 
b)(9). Also, as per John Dunning’s (10) ownership location and internalisation (OLI) 
approach  ownership specific location, location specific and internalisation specific 
ownership advantage create monopolistic advantages which can be used to prevail in 
market abroad. The Ownership, Localisation and Internalization (OLI) paradigm of John 
Dunning shows that under certain conditions it becomes profitable for the investor to 
produce in foreign market. Thus this research intends to anatomize the relationship 
between the FDI and higher patent protection by measuring the strength of factors of 
investment climate (including higher patent protection for biopharma) in attracting the 




The basic question which has been addressed in this paper is the role of product patent 
protection in stimulating technology transfer for the biopharma drugs innovation in 
Indian biopharma sector and to what extent differences in investment climate of different 
states of India affects inflow of foreign direct investment and technology transfer? 
Methodology 
 
The paper has addressed these questions using a industry level FDI and foreign 
technology transfer data collected from Foreign Investment Promotion Board (FIPB), 
Ministry of commerce and Industry, Government of India as well as firm-level database 
derived from the interviews of the biopharma multina onal companies (MNC) heads 
based in India. The survey has covered 10 biopharma MNC firms based in India. The 
study has selected 5 Indian states: Maharashtra, Guj rat, Andhra Pradesh, Karnataka, and 
Delhi for the research which forms biocluster of India. Also in these five states out of 
total 142 biopharma firms in India more than 130 (9%) firms are located in just 5 states, 
in Andhra Pradesh 38 (27%), Maharshtra 38 (27%), Karnat ka 17 (12%), Delhi 16 
(11%)(15) and Gujarat which form the Indian biocluster whose Investment climate (IC) 
grading or ranking has done by the World Bank it its survey of 2000 and 2003. The study 
has taken support of World Bank FACS IC survey of Indian states 2000 and 2003. 
On the basis of collected data from Ministry and IC data of World Bank the relationship 





For measuring the impact of product patent protection, data has been collected from 1991 
to 2005. 1991-1999 to see post libralisation effect and pre TRIPs effect and 1999 – 2005 
(post TRIPs). TRIPs agreement came into effect on Ja uary 1st 1995, it set out 
transitional period of 10 years (until 2005) for the implementation of the TRIPs 
agreement for the developing countries like India, which had not granted patents for 
pharmaceutical products. India had however, accepted applications (the mail box 
provision) (11) and, beginning in 2000, offered “exclusive marketing rights (EMR) by the 
Patent amendment Act 1999. EMR are very similar to patents in offering monopoly 
marketing rights to the inventor, so effectively product patent protection was available 
since 1999. Thus, for analyzing impact of product patent protection on the 
biopharmaceutical innovation, the time period of year 2000 to March 2005 has been 
considered. 
Two types of data have been collected for the survey, first industry level and second firm 
level. Industry level data on the flow of foreign technology transfer has been collected 
majorly from foreign investment promotion board (FIPB), Ministry of Industry and 
commerce. Firm level data has been collected from the biopharma firms (MNC which are 
based in India). This has been done by visiting indiv dual biopharma MNCs based in 
India such as Novo Nordisk, Aventis pharma, Glaxo smithcline, Eli Lily and Co, LG 
Chemicals, Astrazeneca etc in order to know their the factors which influenced their 
decision to invest in India. Survey has been done by interviewing CEOs personally these 
firms personally which are located in these states mainly in Bangalore, Hyderabad, 
Mumbai, Pune, Delhi, Gurgaon etc from July 2006 to January 2007.  
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The study has employed graphical analysis as well as interview analysis to answer the 
research question.  
Case Study 
 
If we see the number of foreign collaborations in Indian biopharma industry in the initial 
years of libralisation then we find that the change in the liberalization policy did not yield 
dramatic results immediately. By libralisation we mean the economic reforms in India 
which started in the early 1990s, or to be more precise, in July 1991. These reform 
processes and the liberalisation of the economy continued throughout the decade and into 
the 21st century. In brief, the reforms include flexible exchange rates regime, full 
convertibility of current account transactions and removal of many international trade 
restrictions, transfer in India by the announcement of the new industrial policy in July 
1991.  
After 1991, with the libralisation (12) of the Indian economy, foreign investment started 
flowing into various sectors of the India ranging from the manufacture of cereals to the 
IT industry. However, by analysing the technology transfer data ranging from 1991 to 
March 2005, it can be inferred that the Indian biopharmaceutical industry did not attract 
much foreign investment in the initial years of libralisation (See chart 1). 
As per chart 1 there is increase in the technology transfer trend though the increase is not 
sharp and continuous. The chart 1 also shows that the number of technology transfer 
cases has increased in post TRIPs era although not sharply as there are ups and downs in 
the flow. So, it cannot be said for sure that the strong IPR leads to an increase in foreign 
investment alone because if it is product patent protection only then the trend would have 
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been sharp and continuous. Therefore it can be inferred that there are other factors as well 
which affect the foreign technology transfer. At the same time it can also be said for sure 
that product patent is one factor which influence technology transfer in the Indian 
biopharmaceutical sector. 
Chart 1: Total number of technology transfer cases in Indian Biopharmaceutical sector 























Source: Foreign Investment Promotion Board, Ministry of Commerce and Industry, Government of 








Chart: 2: FDI in Indian biopharmaceutical and pharma sector 
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Source: Foreign Investment Promotion Board, Ministry of Commerce and Industry, Government of 
India, 2005 
By examining the trend of technology transfer in Indian biopharma sector carefully, it can 
be seen that the flow has increased more sharply in the post TRIPs era (1999- 2005 
March ) than in pre TRIPs period (between 1991 to 1999) (see Chart 2). 
Similar trend has been found in FDI flow in Indian pharma industry (see Chart 2). The 
trend of FDI flow is more or less the same in both the sectors and the same has increased 
more in post TRIPs period (1999- 2004). The foreign nvestment flow in Indian 
biopharmaceutical sector is sharper in 2000- 2004 period (total FDI during this period is 
40.12 US $ million) than 1995 - 2000 period (total FDI during this period is 83.12 US $ 
million). The total amount of investment undertaken by foreign firms during 2000–March 
2005 stood at $83.12 million, more than double the inv stment they had undertaken over 
1995–2000 $40.12 million) (Table1). The total flow of FDI into biopharma sector was 
$16.22 million between 1991 and 1994 which increased five times during 2000 and 
March 2005. Such trend can be seen as a result of increasing interest in the Indian 
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biopharmaceutical industry through direct investment. As a consequence, the share of 
biopharmaceuticals in the total FDI inflows has increased from 2.4 per cent from 1995 
to1999 which further increased to 4.9 per cent from 2000 to March 2005. The result 
shows that India’s shifting from a weak patent regime to a stronger patent regime has 
taken place during this period and this final shift in the patent regime might have 
promoted hesitating foreign enterprises to enter into I dian market. The actual FDI 
inflow into Indian biopharmaceutical industry is estimated to be only $ 47.57 million in 
2005 which is just 2.4% of the total amount $2171 million received by the economy 
although it has increased from 1991 which was around 1% of the total FDI (Table 1).  
Table 1: 
Comparision of the statement of yearwise breakup for Foreiign Direct Investment (FDI) & Foreign 
Technology Cases approved by Government during August 1991 to December 2005 in Drugs & 
pharma  and biopharma sector 
 
Year Amount of FDI 
approved in all sectors 
(in US $ millon) 
Amount of FDI 
approved in Drugs and 
pharma sector (in US 
$ millon) 
Amount of FDI 
approved in 
Biopharmaceutical 
sector (in US $ millon) 
1991 165 0.32 nil 
1992 383 11.13 3.76 
1993 654 9.76 3.76 
1994 1374 51.91 4.35 
1995 2141 59.54 4.35 
1996 2770 34.37 8.36 
1997 3682 50.99 4.77 
1998 3083 23.07 Nil 
1999 2908 18.55 0.14 
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2000 4222 70.85 26.85 
2001 3134 82.82 0.33 
2002 2634 28.03 18.35 
2003 3754 51.92 16.87 
2004 2171 188.01 47.57 
2005  7.23 .71 
TOTAL  688.51 131.57 
Source: Foreign Investment Promotion Board, Ministry of Commerce and Industry, Government of India 
 
This also shows that the foreign technology flow is increasing but not very smooth and 
sharp  
and the reason can be given that as the product patent protection has been imposed in 
India in 2005 and this is the effect of the transition period from EMR (13) protection to 
product patent protection. So, the actual effect of pr duct patent protection may not be 
visible as yet. On such trend, it can be interpreted that though, the advent of product 
patent did not bring dramatic increase in FDI flow in IP driven industry such as drugs and 
pharma but trend may be sharper with the years to come as product patent protection has 
just imposed in the biopharma sector. 
Along with the above analysis and discussions to be more accurate in finding the actual 
relation between the product patent protection and foreign technology flow in biopharma 
sector, the same relationship has been further examined by interview data to validate the 
outcome stated above. For the same, field research has been done and in the same field 
research, 10 CEOs and director level officials of Biopharma MNCs were interviewed and 
asked about the most influencing factor in making decision to invest in India. These 
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MNCs are also located in different bioclusters of the country- Bangalore, Hyderabad, 
Mumbai – Pune, Delhi and Gurgaon. They were given 7 factors to grade them according 
to their preference. Factors were Intellectual prope ty Rights, quality and implementation, 
stability of Indian partner, management skills, bureaucracy, market, geographical 
distance. On 15 scale value 12 scale values was given to stronger patent protection or 
higher intellectual property rights.  (See Chart 3).    
Chart: 3 Comparative Importance of Factors in Decision of Technology Transfer      
 
 
Comparative importance of factors considered in decision 
making for the transfer of technology in Indian bipharma 



























































































Source:  based on own Research 
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So, by looking at this trend, it can be said that cer ainly stronger patent protection is one 
of the strongest factor which has influenced the foreign MNCs to transfer their 
technology to India which seem to increase with time. At the same time other factors also 
influence the decision of making the foreign investment such as regulatory policies, fiscal 
policy, infrastructure, bureaucracy etc along with patent policy.  
From the above finding it is clear that changed IP protection is one of the components of 
the investment climate. The change in patent protecti n imposed equally all over the 
India and if IP is the only factor which influence the FDI flow in sector like biopharma 
then the flow of FDI should be more or less the same in all the biocluster states. To be 
surer about the role of IP in pulling FDI into Indian biopharmaceutical sector the foreign 
technology transfer data collected from FIPB has been further divided state wise and then 
relationship of the same had been measured by the investment climate of the state. For 
the data on the investment climate of different stae  of India the paper has taken the data 
provided by the World Bank in its joint survey with Confederation of Indian Industries 
(CII) in 2000 and 2003. 
The World Bank has conducted surveys  FACS in 2000 (14) and in 2003 (15) by jointly 
with Confederation of Indian Industries in which 12 states and large number of industries 
were covered which include: (i) Food processing, (ii) Textiles, (iii) Garments, (iv) 
Leather goods, (v) Pharmaceuticals, (vi) Electronic consumer goods, (vii) Electrical 
white goods, (viii) Auto components, (ix) Metal and metal products, (x) Plastics, and (xi) 
Machine Tools. Since the pharmaceutical industry is covered so the survey is relevant 
base our findings on the same. In this survey the business managers were asked to 
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identify the states that they thought had a better or worse IC than the state in which they 
were currently based. They were also asked to say which of the states in their opinion had 
the best IC and which had the worst. The subjective ranking of the states according to IC, 
as expressed by the business managers, is presented in Table 2. 
 
 
Table 2: Subjective Ranking of Best to Worst IC (FACS 2000) 
 
Category States  
 
 




2. Drugs and 
pharmaceuticals 
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3. Andhra Pradesh 
4. Karnataka 
5. Tamil Nadu 
 
    









Poor Investment Climate 
 
8. Kerala 
9. West Bengal 
10. Uttar pradesh 
 
 

















Source: Estimates provided by the World Bank 2003 
 
The paper has tried to find the match or relationship between the FDI data collected from 
FIPB and the World Bank data of IC of the Indian states and then tries to find the results. 
For the same the complete FDI data of 1991 to 2005 has been rearranged state wise (see 
Table: 4). Table 4 shows that maximum number of foreign collaboration took place in 
western cluster which is formed by Maharashtra and Gujarat. Now if we see the 
investment climate of these states then we will find that these two states have the best IC 
in country as in the 2000 survey Maharashtra stood at the first place whereas Gujarat 
stood second. Although in 2003 survey Gujarat lost its position from best IC state to 
Good IC state but remained at the top among the good IC states. In 2003 too Maharashtra 
Category States % say best minus % say 
worst 
 




Good Investment Climate 3. Gujarat 
4. Andhra Pradesh 
5. Karnataka 
6. Punjab 








Poor Investment Climate 9. Madhya Pradesh 
10. Kerala 
11. West Bengal 
12. Uttar Pradesh 
           -6.8 
          -15.0 
          -30.6 
          -30.6 
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maintained its position as the best IC state therefore it can be interpreted that the FDI 




 FDI in Indian states between 1991 and 2005 
 
 
Source: Foreign Investment Promotion Board, Ministry of Commerce and Industry, Government of 
India, 2005 
 
As per the FIPB FDI data the second highest foreign collaborations happened in Southern 
cluster which is formed by Andhra Pradesh and Karnat ka, if we see the investment 
climate of these states the we will find that these two states are in Good IC states and are 
just behind Maharashtra and Gujarat in 2000 survey whereas in 2003 survey these states 
are at 4th and 5th postion so overall from 1991 to 2005 this cluster maintained the second  
best IC states position which is directly correlated with the second highest FDI flow 
which flowed around 26.532 %  of the total FDI flow in the country after the western 
cluster of 38.775%. 
Now if we see the IC state of the northern cluster which comprise of Delhi and Utter 
Pradesh then we will find that in 2000 survey Delhi was in the category of medium IC 
states whereas UP was placed in the poor IC state. Although Delhi’s IC improved and it 




transfer cases  
Percentage 
Southern 26 26.532 
Western 38 38.775 
Northern 14 14.285 
States not indicated 20 20.408 
Total 98 100 
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FDI flow in this region flowed less than western and southern cluster may be because the 
calculation of FDI is from 1991 to 2005 and till 2000 the IC of Delhi was at 6th position 
and still Maharashtra occupies the best states position and Gujarat also remained at the 3rd 
position. Among the southern cluster states also these states maintained their position in 
the good IC states throughout therefore it can be said that it remained second choice for 
the foreign investors to invest. 
Thus this research finds that the factors of locatin advantage is important for the foreign 
investment destination in the local market, which includes factors like resource 
endowment and also economic and social factors suchas market size and structure, 
prospect for market growth and degree of development, the cultural, legal, political and 
institutional environment and Government legislation and policies of the different states 
of India. In terms of the demand side factors, the host’s overall attractiveness to FDI is 
determined by location advantages it possesses or the investment climate of the country. 
As resource endowments are not evenly distributed among countries and social and 
economic factors as well as Government policies are diff rent among countries, even it is 
different among the states of the same country, the a tractiveness different states in India 
for FDI is different. In biopharma sector attractiveness of the location in country like 
India depends on the cost advantage in clinical tris and labour as these are largely the 
factors which affect the drug development cost significantly (10). Biotechnology is a 
knowledge-driven sector because it consists of knowledge working on knowledge to 
create value, decoding in genomics and proteomics being paradigmatic knowledge-based 
economic activity. In the case of biotechnology, foreign investments are key magnets for 
the Indian biopharma industry to shift to novel innovation in change patent regime. Since 
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transfer science from the laboratory bench to the market involves complex, interactive 
chains of transactions among scientists, entrepreneu s, and various intermediaries 
therefore proximity to services such as investors and lawyers and, in biotechnology, 
research hospitals for clinical trials are important which also create an innovation system. 
These factors form the factors of investment climate. Since patent policy has changed and 
applied uniformly to whole of the India but other factors of the investment climate differs 
state to state therefore foreign investment has been also flowed according to the 
investment climate of the states. 
Thus, form the above analysis it is clear that the factors of investment climate play their 
role in influencing the decision of the investment a d Intellectual property is the one 
factor among the different factors of investment climate which influence the decision of  
foreign investment. Therefore the paper concludes that product patent protection is 
certainly worked as stimulant to pull foreign investment in Indian biopharma industry but 
it is not the only factor as there are other factors f investment climate which affect the 
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